Overview

Dapagliflozin in Depression

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-20
Target enrollment:
Participant gender:
Summary
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression
Phase:
PHASE1
Details
Lead Sponsor:
Tanta University
Treatments:
dapagliflozin
Fluoxetine